Global CD47 (IAP) Market Growth (Status and Outlook) 2024-2031

Report ID: 1780769 | Published Date: Jan 2025 | No. of Page: 114 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

As the global economy mends, the 2021 growth of CD47 (IAP) will have significant change from previous year. According to our (LP Information) latest study, the global CD47 (IAP) market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global CD47 (IAP) market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States CD47 (IAP) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global CD47 (IAP) market, reaching US$ million by the year 2028. As for the Europe CD47 (IAP) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main CD47 (IAP) players cover Gilead, Innovent Biologics, Akeso, Inc, and Arch Oncology, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of CD47 (IAP) market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Solid Tumor
Lymphoma
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx

Frequently Asked Questions
Global CD47 Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Global CD47 Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Global CD47 Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports